Literature DB >> 19306899

Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in-vitro.

Ahmed M Al-Abd1, Soo Hyeon Lee, Sun Hwa Kim, Jung-Ho Cha, Tae Gwan Park, Seung Jin Lee, Hyo-Jeong Kuh.   

Abstract

A polyelectrolyte complex(PEC) micelle-based siRNA delivery system has been developed for vascular endothelial growth factor (VEGF), and its antitumor efficacy has been demonstrated using in-vivo animal models. Penetration and distribution through the avascular regions of human solid tumors after extravasation are important issues for antitumor efficacy, especially for macromolecules such as VEGF siRNA PEC micelles. Using an in-vitro solid tumor model, multicellular layers(MCL) culture of human colorectal cancer cells, we evaluated the penetration kinetics and efficacy of VEGF siRNA PEC micelles(PEC-siRNA) in comparison to unmodified siRNA(N-siRNA). The PEC-siRNA showed full penetration (15-17 layers of cells) with a unique punctuated distribution pattern at 48 h following initial accumulation in the top layers and a significant suppression of mRNA and protein expression in a dose-dependent manner after 72 h exposure. Although the initial penetration of N-siRNA was faster than that of PEC-siRNA, N-siRNA showed complete loss of activity due to its instability within 24 h. Our data support the idea that PEC micelle formulation may provide stable penetration tool through the multilayers of cancer cells and ensure the gene silencing effect of VEGF. This study also demonstrated that MCL could serve as a useful in-vitro model to evaluate the dose- and time-dependent profiles of penetration and efficacy of macromolecular delivery systems in human solid tumor avascular regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306899     DOI: 10.1016/j.jconrel.2009.03.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

1.  Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug.

Authors:  Ahmed M Al-Abd; Alaa Khedr; Salah G Atteiah; Fahad A Al-Abbasi
Journal:  Saudi Pharm J       Date:  2020-05-11       Impact factor: 4.330

Review 2.  Self-assembled and nanostructured siRNA delivery systems.

Authors:  Ji Hoon Jeong; Tae Gwan Park; Sun Hwa Kim
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

Review 3.  Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Crit Rev Biomed Eng       Date:  2012

4.  Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation.

Authors:  Lin Zhu; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2010-10-21       Impact factor: 4.774

5.  Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery.

Authors:  Teerapong Yata; Koon-Yang Lee; Tararaj Dharakul; Sirirurg Songsivilai; Alexander Bismarck; Paul J Mintz; Amin Hajitou
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-12       Impact factor: 10.183

6.  Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.

Authors:  Zhen Zhao; Yuanke Li; Ravi Shukla; Hao Liu; Akshay Jain; Ashutosh Barve; Kun Cheng
Journal:  Theranostics       Date:  2019-06-09       Impact factor: 11.556

7.  Tissue distribution and efficacy of gold nanorods coupled with laser induced photoplasmonic therapy in ehrlich carcinoma solid tumor model.

Authors:  Mostafa A El-Sayed; Ali A Shabaka; Osama A El-Shabrawy; Nemat A Yassin; Sawsan S Mahmoud; Siham M El-Shenawy; Emad Al-Ashqar; Wael H Eisa; Niveen M Farag; Marwa A El-Shaer; Nabila Salah; Ahmed M Al-Abd
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

Review 8.  Functional nanostructures for effective delivery of small interfering RNA therapeutics.

Authors:  Cheol Am Hong; Yoon Sung Nam
Journal:  Theranostics       Date:  2014-09-19       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.